

May 2, 2016

Press Release

Company	GreenPeptide Co., Ltd.
Representative	Kenichi Nagai, President & CEO (Code: 4594 TSE Mothers)
Inquiries	Teruhiko Sakai, Director/CFO (TEL.03-5840-7697)

Completion of Patient Enrollment in Japanese Phase III Clinical Study on
GreenPeptide's Lead Product Candidate ITK-1

GreenPeptide today announced that the completion of patient enrollment for the ongoing placebo-controlled phase III clinical study on ITK-1 for prostate cancer (the study) in Japan. ITK-1 is a product candidate that we have out-licensed to Fuji Film Corporation (Headquarters Tokyo), and the study is outsourced to GreenPeptide now.

This is a double-blind placebo-controlled clinical study on a cancer peptide vaccine developed in Japan and is being conducted on patients with advanced castration-resistant prostate cancer* in whom surgery, radiotherapy, hormone therapy and chemotherapy (anticancer agents) have failed, at more than 60 study sites nationwide. Commencing in August 2013, patient enrollment for the study was completed in April 2016 thanks to close cooperation with the study sites concerned.

Phase III clinical study will be completed after a follow-up period and great attention will continually be paid to safety as the study progresses.

The completion of patient enrollment for the current study will have a minimal effect on GreenPeptide's results for the year to March 2016 (from April 1, 2016 to March 31, 2017). In addition, the company will disclose the effect of this on the forecast for our results in the year to March 2017 when we announce our results for the year to March 2016 on May 13, 2016.

【Explanation of Term】

*Castration-resistant prostate cancer: Prostate cancer is a type of cancer specific to males, which male hormones cause to grow. Generally, following surgery or radiotherapy, hormone therapy (endocrine therapy) is conducted to suppress male hormones.

Although efficacy is achieved in the initial phase of hormone therapy, after a while, the cancer recur, continued treatment becomes less effective and the cancer may start to grow again. This condition is referred to as castration-resistant prostate cancer.

【About GreenPeptide Co., Ltd.】

GreenPeptide is a drug discovery venture company engaged in the research and development of cancer immunotherapies that make use of the body's immune system to fight cancer. There are hopes that cancer immunotherapy will be the 4th therapy when surgery, radiotherapy and chemotherapy have failed.

Having 2 cancer peptide vaccines (ITK-1 for prostate cancer, GRN-1201 for malignant melanoma) as mainstay products, GreenPeptide aims to contribute to innovation in cancer therapy through the creation of novel cancer immunotherapies that disseminate a new drug discovery concept originating in Japan worldwide.